CINECA IRIS Institutional Research Information System

TRUNFIO, MATTIA GIOVANNI CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.270
EU - Europa 1.089
AS - Asia 867
SA - Sud America 166
AF - Africa 84
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.501
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.218
IT - Italia 409
SG - Singapore 287
CN - Cina 206
IE - Irlanda 171
SE - Svezia 98
DE - Germania 68
ID - Indonesia 68
VN - Vietnam 67
IN - India 60
AT - Austria 59
GB - Regno Unito 55
FR - Francia 54
CO - Colombia 53
BR - Brasile 44
AR - Argentina 32
ES - Italia 29
HK - Hong Kong 25
CA - Canada 24
FI - Finlandia 24
AU - Australia 23
TH - Thailandia 23
MX - Messico 22
IR - Iran 21
NL - Olanda 21
ZA - Sudafrica 19
PE - Perù 18
JP - Giappone 17
PH - Filippine 17
MY - Malesia 16
KR - Corea 13
KE - Kenya 12
TW - Taiwan 12
UA - Ucraina 12
BE - Belgio 11
GR - Grecia 10
RU - Federazione Russa 10
TR - Turchia 10
CZ - Repubblica Ceca 9
CL - Cile 8
NG - Nigeria 8
TZ - Tanzania 8
UG - Uganda 8
PY - Paraguay 7
CH - Svizzera 6
PL - Polonia 6
PT - Portogallo 6
SA - Arabia Saudita 6
DZ - Algeria 5
HU - Ungheria 5
IL - Israele 5
DK - Danimarca 4
KH - Cambogia 4
MW - Malawi 4
PK - Pakistan 4
RE - Reunion 4
RO - Romania 4
BG - Bulgaria 3
CR - Costa Rica 3
EG - Egitto 3
LT - Lituania 3
NO - Norvegia 3
BA - Bosnia-Erzegovina 2
CD - Congo 2
EC - Ecuador 2
GH - Ghana 2
HN - Honduras 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NA - Namibia 2
TG - Togo 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GT - Guatemala 1
HR - Croazia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
SD - Sudan 1
UY - Uruguay 1
YE - Yemen 1
ZW - Zimbabwe 1
Totale 4.501
Salva come PNG Salva come JPEG
Città #
Chandler 374
Singapore 237
Santa Clara 225
Dublin 169
Fairfield 113
Ashburn 98
Turin 97
Torino 82
Redwood City 80
Columbus 76
Nyköping 67
Medford 61
Beijing 54
Wilmington 50
Woodbridge 50
Jakarta 48
Princeton 45
Cambridge 38
Houston 35
Ann Arbor 33
San Diego 30
Jacksonville 29
Seattle 29
Milan 27
Hangzhou 22
New York 21
Hebei 19
Buenos Aires 17
Dong Ket 16
Guangzhou 16
Frankfurt am Main 15
Helsinki 14
Lima 14
Medellín 14
Vienna 14
Dearborn 13
London 13
Seoul 13
Washington 13
Hong Kong 11
Paris 11
Brussels 10
Cartagena 10
Melbourne 10
São Paulo 10
Grugliasco 9
Ho Chi Minh City 9
Mumbai 9
Ottawa 9
Rio de Janeiro 9
Upper Marlboro 9
Bangkok 8
Lappeenranta 8
Nanjing 8
Pisa 8
Villeurbanne 8
Barcelona 7
Barranquilla 7
Chengdu 7
Duncan 7
Falls Church 7
Guiyang 7
Johannesburg 7
Kuala Lumpur 7
Los Angeles 7
Norwalk 7
Raleigh 7
Riverton 7
Santiago 7
Yekaterinburg 7
Abuja 6
Brno 6
Central 6
Chandigarh 6
Chicago 6
Fredericton 6
Genoa 6
Hanoi 6
Hefei 6
Rome 6
Algiers 5
Boston 5
Guadalajara de Buga 5
Gurgaon 5
Istanbul 5
Jinan 5
Kampala 5
Nanterre 5
Nuremberg 5
Pune 5
Richmond 5
Sydney 5
Tainan City 5
Bengaluru 4
Bologna 4
Buffalo 4
Cape Town 4
Central District 4
Chapel Hill 4
Cinisello Balsamo 4
Totale 2.788
Salva come PNG Salva come JPEG
Nome #
Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern 429
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 268
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 232
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 166
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 148
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series 143
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders: Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients 137
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 134
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy 131
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections 120
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? 112
Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study 106
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients 83
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 82
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection 80
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity 80
Co-infection with other respiratory pathogens in COVID-19 patients 75
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases 74
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders 71
The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes 69
Ultrasonography of an oral cavity onchocercidae nodule 69
Blood–brain barrier impairment in patients living with hiv: Predictors and associated biomarkers 67
The manifesto of pharmacoenosis: Merging hiv pharmacology into pathocoenosis and syndemics in developing countries 65
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases 63
Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient 63
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 62
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 61
Alzheimer Dementia in People Living With HIV 60
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 58
Screening Accuracy of Mini Addenbrooke’s Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV 54
Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review 54
Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis 53
JC virus DNA in cerebrospinal fluid: insight into clinical significance 50
HIV-1 detection in the olfactory mucosa of HIV-1 infected participants 50
COVID-19: A Possible Contribution of the MAPK Pathway 48
Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy 48
Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: A parallel cohort study in healthcare workers 47
Clinical and VIRO-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients 46
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition 46
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 44
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 43
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 41
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs 41
Concurrent and Subsequent Co-Infections of Clostridioides difficile Colitis in the Era of Gut Microbiota and Expanding Treatment Options 39
Malignant melanoma in people living with HIV/AIDS: Can we know more, can we do better? 35
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV 34
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia 33
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 33
Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV 32
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases 31
Norepinephrine may improve survival of septic shock patients in a low-resource setting: a proof-of-concept study on feasibility and efficacy outside the Intensive Care Unit 31
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 28
Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants 26
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV 25
What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? 25
Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART) 25
The role of antirheumatics in patients with COVID-19 24
Beyond the Syndemic of Opioid Use Disorders and HIV: The Impact of Opioids on Viral Reservoirs 21
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen 19
Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV 18
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review 16
Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV 14
Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV 14
Living with HIV and Getting Vaccinated: A Narrative Review 12
Use of different anticholinergic scales and their correlation with anticholinergic symptom burden in a cohort of people living with HIV 12
Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV 11
Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA 11
Staphylococcus aureus meticillino-resistente 11
The presence of resistance-associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV-1 escape: A multicentric retrospective analysis 10
Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 9
Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and Omicron era: A real‐life cohort study 8
Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis 8
Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV 8
Use of self-prescribed medications and complementary medicines in a cohort of women with HIV 7
Cognitive criteria in HIV: greater consensus is needed 7
Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV 6
PRESENCE, COMPOSITION AND NEUROINFLAMMATORY CORRELATES OF THE CEREBROSPINAL FLUID VIROME IN ANTIRETROVIRAL TREATED PEOPLE WITH HIV ACROSS DIFFERENT METAGENOMIC PIPELINES 5
Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study 4
Association between tight junction proteins and cognitive performance in untreated persons with HIV 3
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial 2
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare 2
Central Nervous System Disorders with Auto-Antibodies in People Living with HIV 2
Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation 2
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study 2
Totale 4.638
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020173 0 0 0 0 0 0 24 21 25 23 30 50
2020/2021419 20 22 37 18 39 22 32 12 16 67 50 84
2021/2022787 58 50 35 42 61 70 42 51 22 77 121 158
2022/20231.200 93 123 51 123 98 268 73 95 97 39 81 59
2023/2024868 94 113 47 47 63 116 57 56 22 76 54 123
2024/2025999 60 141 91 159 360 155 33 0 0 0 0 0
Totale 4.638